News

AZ sells rights to GI drug Entocort for $215m


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

AZ sells rights to GI drug Entocort for $215m

Date: 13/07/2015


AstraZeneca has sold Tillotts Pharma rights to gastroenterology drug Entocort for $215 million, under a bid to hone its focus on core areas such as cancer and diabetes.

Tillotts Pharma, a Swiss-based subsidiary of Japanese group Zeria, is picking up global rights (excluding the US) to the drug, which is marketed for Crohn's disease and ulcerative colitis. 

For more click here

Source: PharmaTimes

© Catalyst Innovation Portal 2019